糖心视频

posted Tuesday afternoon, has raised approximately $47.5 million in new funding. The Cambridge, MA-based company researches and develops therapeutics based around the human microbiome, the ecosystem of flora and fauna that take up residence in the warm, dark confines of our guts, mouths, blood, reproductive systems, and elsewhere.

Follow Crunchbase News on &

It turns out that the bacteria and other microorganisms that live inside us have seemingly profound effects on health and wellness, and researchers are discovering ways to use our microbiota to treat and prevent disease.

According to the , Evelo Biosciences is exploring applications in oncology (cancer treatment and research), central nervous system issues like anxiety and depression, neurodegenerative diseases like Alzheimer鈥檚 and Parkinson鈥檚, autoimmune diseases like rheumatoid arthritis, and metabolic conditions like liver disease and obesity, among other fields.

The company holds several patents, including one for , and it to develop, , trial, and commercialize a possible way to treat or prevent cancer by manipulating the human microbiome.

Evelo Biosciences was founded in 2014 and has raised at least . Investors include聽 (Google Ventures, an occasional investor in life sciences startups), , , and .

鈥攁 venture fund with at least 鈥攍ed Evelo鈥檚 Series A and Series B rounds. A life sciences investor told Crunchbase News that Flagship Pioneering has a similar model to a 鈥渧enture studio鈥� in that they conceive of, create, and fund 鈥渇irst-in-category鈥� startups in the life sciences sector. The founding partner and managing director of Flagship Pioneering, , is according to Crunchbase data.

Comparing the new SEC filing to declaring the company鈥檚 , no new board members or executives are listed. Other notable directors listed on this and previous filings include of , and of Flagship Pioneering, of (another Flagship-funded company), and , a British Labour politician and Chair of Surgery at Imperial College London.

Crunchbase News has reached out to Evelo Biosciences seeking comment but did not hear back prior to publication.

滨濒濒耻蝉迟谤补迟颈辞苍:听